English, Article edition: Cost-Effectiveness Analysis of Antiplatelet Therapy in the Prevention of Recurrent Stroke in the UK: Aspirin, Dipyridamole and Aspirin-Dipyridamole Mike Chambers; John Hutton; John Gladman

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118768
Physical Description
  • article
Language
  • English

Edition details

Title
  • Cost-Effectiveness Analysis of Antiplatelet Therapy in the Prevention of Recurrent Stroke in the UK: Aspirin, Dipyridamole and Aspirin-Dipyridamole
Author
  • Mike Chambers
  • John Hutton
  • John Gladman
Physical Description
  • article
Notes
  • Objectives: To evaluate the cost effectiveness from a UK health and social services perspective of antiplatelet therapies tested in the Second European Stroke Prevention Study (ESPS-2) in preventing recurrent stroke. To demonstrate the value of modelling studies in this area. Design and setting: A decision-analytic model was developed to evaluate health outcomes and associated costs. Sources of data for efficacy, adverse events, background event risks, disability and mortality were ESPS-2, the Oxfordshire Community Stroke Project and UK national statistics. Published national unit costs were applied to clinician panel estimates of resource use for acute stroke, rehabilitation and long term care. Outcome measures were strokes or disabled life-years averted, and disability-free, stroke-free or quality-adjusted life-years gained. Patients and interventions: 30-day survivors of ischaemic stroke treated with low dose aspirin, modified-release dipyridamole; the coformulation of low dose aspirin plus modified-release dipyridamole, or no antiplatelet therapy. Main outcome measures and results: The model predicted that over 5 years the coformulation prevented 29 more strokes than aspirin alone per 1000 patients, at an additional cost of Lstg 1900 per stroke averted (1996 values). Over 5 years, each antiplatelet therapy was cost saving compared with no therapy. Results were sensitive to the cost of acute care, the cost of long term care of disabled stroke survivors, the effectiveness of therapy and the background risk of recurrent stroke. In sensitivity analyses, the cost effectiveness did not exceed Lstg 7000 per stroke averted or Lstg 11 000 per quality-adjusted life-year (QALY) gained, except when varying the effectiveness parameter. Conclusions: Application of a decision-analytic model to the results of ESPS-2 indicated that first-line therapy with the coformulation of modified-release dipyridamole and low dose aspirin to patients with a previous ischaemic stroke is likely to generate significant health benefits at modest extra costs to health and social services. The extra costs of treatment are balanced by the savings in future costs of acute care and long term care of the disabled. Future economic evaluations in this area should pay particular attention to the cost perspective, the duration of analysis, the selection of trials from which effectiveness data are derived, and the impact of the pooling of outcome events with potentially different economic consequences.
  • Pharmacoeconomics, Aspirin, Dipyridamole, Stroke, Cost-effectiveness, Resource-use, Antithrombotics
  • RePEc:wkh:phecon:v:16:y:1999:i:5:p:577-593
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment